Skip to content
DataLookout
Menu

NCT07229820

Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words
    • Trial completed
    • Study completion date changed from estimate of Dec 31, 2025 to Jan 25, 2026
    • Study title revised
  2. Minor Trial status: Recruiting to Active, Not Recruitingv3 Show 4 more changesShow less
    • Enrollment target: estimated 150 to confirmed 157
    • Primary completion date: Jul 17, 2026 to Dec 22, 2025
    • Study completion date: Nov 17, 2026 to Dec 31, 2025
    • Site details revised
  3. Minor Start date changed from estimate of Nov 30, 2025 to Nov 8, 2025v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to Alleviation of Symptoms
Timeframe: DAY1~DAY15

Secondary (2)

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Plasma concentrations of ZSP1273

Arms and interventions

ZSP1273Experimental
PlaceboPlacebo comparator

Drugs: ZSP1273, Placebo

Sites

1 site in 1 country

  • Ruijin HospitalShanghai, China